Clinical and Molecular Characteristics of X-Linked Agammaglobulinemia Patients 55 Years or Older.
Chin AT, Ochs HD, Kobayashi R, Abolhassani H, Alachkar H, Barmettler S, Baxendale H, Boiling K, Catanzaro J, Chua I, Coulter T, Cunningham-Rundles C, Elcombe SE, Fischer A, Grimbacher B, Gupta S, Herriot R, Herwadkar A, Imai K, Inoue S, Kirkpatrick C, Knutsen AP, Kumararatne D, Lea E, Lin MW, Litzman J, Mahlaoui N, Moriya K, Nonoyama S, Patel S, Perez E, Quinti I, Hostoffer RW, Rothenfusser S, Sargur R, Shields A, Sogkas G, Suan D, Tan T, Thomas M, Warnatz K, Younger EM, Kuo CY.
Chin AT, et al.
J Allergy Clin Immunol Pract. 2025 Oct;13(10):2806-2816.e6. doi: 10.1016/j.jaip.2025.06.025. Epub 2025 Jun 24.
J Allergy Clin Immunol Pract. 2025.
PMID: 40571245
BACKGROUND: X-linked agammaglobulinemia (XLA), caused by mutations in the Bruton tyrosine kinase (BTK) gene, leads to defective B-cell development and low or absent serum immunoglobulins. ...
BACKGROUND: X-linked agammaglobulinemia (XLA), caused by mutations in the Bruton tyrosine kinase (BTK) gene, leads to d …